Pivotal Point Follow-Up Verastem (VSTM): Biotech Breakthrough in Pancreatic Cancer - 50% Response Rate and $250 Million for Phase 3

Verastem is a US biotechnology company developing targeted therapies against cancer-promoting gene mutations in the RAS/MAPK signaling pathway. On October 15, 2026, the stock celebrated a Pivotal Point after strong data on the drug VS-7375. In a study for advanced pancreatic cancer, the oral medication achieved an objective response rate of 50%. Furthermore, the company strengthened its financial foundation through the pricing of a capital increase of over $250 million. The biopharma company benefits primarily from the high medical need for hard-to-treat...